p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610

Journal of the National Cancer Institute

Volumn 89, Issue 2, 1997, Pages 158-165

  Grignon, David J ^a,k   Caplan, Richard ^b   Sarkar, Fazlul H ^a   Lawton, Colleen A ^c   Hammond, Elizabeth H ^d   Pilepich, Miljenko V ^e   Forman, Jeffrey D ^a   Mesic, John ^f   Fu, Karen K ^g   Abrams, Ross A ^h   Pajak, Thomas F ^b   Shipley, William U ⁱ   Cox, James D ^j  

^a WAYNE STATE UNIVERSITY   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Latter Day Saints Hospital   (United States)

^e Saint Joseph's Hospital   (United States)

^f Radiological Associates of Sacramento Medical Group Inc   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k HARPER UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; GENE MUTATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031030869     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.2.158     Document Type: Article

References (38)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene [see comment citations in Medline]. N Engl J Med 1993;329:1318-27.
2. Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994;57:623-7.
3. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Becken MA, Virudachalam S, et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-6.
4. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
5. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53:3369-73.
6. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
7. Uchida T, Wada C, Shitara T, Egawa S, Koshiba K. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. Br J Cancer 1993;68:751-5.
8. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL. Mutant p53 expression in prostate carcinoma. Prostate 1993;22:23-30.
9. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Ural 1994;152:1297-301.
10. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-80.
11. Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994;25:92-7.
12. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;145:287-93.
13. Vesalainen SL, Lipponen PK, Talja MT, Alhava EM, Syrjanen KJ. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2MO prostatic adenocarcinoma. Int J Cancer 1994;58:303-8.
14. Losi L, Di Gregario C, Brausi M, Fante R, Hurlimann J. Expression of p53 protein in prostate cancers of different histologic types. Pathol Res Pract 1994;190:384-8.
15. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
16. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994;56:630-3.
17. Myers RB, Oelschlager D, Srivastava S, Grizzle WE. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994;25:243-8.
18. Chen YQ, Gao X, Grignon DJ, Sarkar FH, Sakr W, Honn KV, et al. Multiple mechanisms of p53 inactivation in prostatic carcinoma. Cancer Molec Biol 1994;1:357-67.
19. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
20. Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol. In press.
21. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
22. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group [see comment citation in Medline]. Urology 1995;45:616-23.
23. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffinembedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
24. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85: 53-9.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;5:163-70.
26. Cox DR. Regression models and life tables. J Royal Stat Soc [B] 1972;34: 187-229.
27. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence [see comment citation in Medline]. J Clin Oncol 1990;8:548-55.
30. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, et al. On the use of cause-specific failure and conditional failure probabilities: example from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
32. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
33. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
34. McDonnell TJ. Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
35. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
36. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 1996;155:1685-92.
37. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147:92-101.
38. Karnofsky DA, Burchenal JH. Clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia Univ Press, 1949.